Preinfection laboratory parameters may predict COVID‐19 severity in tumor patients

Alexander Kiani(Bayreuth Medical Center), Ralph Naumann(University of Siegen), Markus Schaich(Rems-Murr-Klinikum), Clemens‐Martin Wendtner(Ludwig-Maximilians-Universität München), Thomas Kubin(Kreisklinik Trostberg), Holger Hebart, Marinela Augustin(Nuremberg Hospital), Helmut Lambertz(Garmisch-Partenkirchen Medical Center), Romina Roesch(Technische Universität Dresden), Ruth Seggewiß-Bernhardt(Sozialstiftung Bamberg), Gerald Illerhaus(Klinikum Stuttgart), Jörg Baesecke(St. Josefs-Hospital Cloppenburg), Jens‐Marcus Chemnitz, Ullrich Graeven(Kliniken Maria Hilf), Ulrich Kaiser(University of Applied Sciences Landshut), Peter Reimer(Essen University Hospital), Frank Hartmann(Universität Hamburg), Markus Kapp(Sana Klinikum), Thomas Südhoff(Klinikum Passau), Martin Bentz(Städtisches Klinikum Karlsruhe), Frank Kullmann(Klinikum Weiden), E. Späth‐Schwalbe(Vivantes Klinikum), Clemens Müller‐Naendrup(Praxis für Hämatologie und Onkologie)
Cancer Medicine
June 13, 2021
10.1002/cam4.4023
Cited by 6

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
|The Lancet Oncology|2016|738
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2015|723